相关实验视频

Updated: Jun 11, 2025

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

皮里多克萨尔-5'-酸盐:高血压患者的经济有效治疗候选人?

Michaela Lellig¹, Mariano Rodríguez^2,3,4, Rodrigo López-Baltanás^2,3

¹Institute for Molecular Cardiovascular Research IMCAR, RWTH Aachen University, Aachen, Germany.

Journal of internal medicine

|October 10, 2024

概括

皮里多克萨尔-5'-酸盐 (PLP) 将血管新生素II转化为Ang P,从而降低大鼠的血压. 这种维生素B6衍生品可能提供一种具有成本效益的高血压治疗.

科学领域:

生物化学生物化学
药理学药理学是指药理学的学科.
心血管科学心血管科学

背景情况:

ангиотензин II (Ang II) 是血管收缩和血压调节中的一个关键.
高血压是一种普遍的心血管疾病,对健康有重大影响.
维生素B6的衍生物皮里多克萨尔-5欧米诺酸盐 (PLP) 价格低廉,并且正在研究其治疗潜力.

研究的目的:

为了研究PLP诱导的Ang II (到Ang P) 的翻译后修改对血压的影响.
评估Ang P对离子进入血管光滑肌细胞 (VSMC) 的影响.
评估Ang P与血管素II型1受体 (AT1R) 的结合亲和力及其血管缩作用.

主要方法:

在实验室中,用PLP对Ang II进行修饰,形成Ang P.
在暴露于Ang P和Ang II的VSMC中测量离子流入.
对Ang P和Ang II与AT1R的结合 afinity 的评估.
评估血管收缩效应使用隔离的透的老鼠脏.
在体内研究中,给自发高血压大鼠 (SHR) 和Wistar京都大鼠 (WKY) 给予PLP.

主要成果:

PLP成功地将Ang II修改为Ang P.
与Ang II相比,Ang P显著减少了VSMC中的离子进入.
与Ang II相比,Ang P对AT1R的结合亲和力较低.
与Ang II相比,Ang P在孤立的老鼠脏中引起的血管收缩较小.
在SHR中,PLP的使用降低了血压,并在WKY大鼠中预防了Ang II诱导的高血压.

结论:

通过PLP介导的Ang II向Ang P的修饰有效地降低了大鼠模型中的血压.
降低Ang P的血管收缩性与减少离子进入和AT1R结合有关.
PLP具有作为高血压的经济有效治疗剂的潜力,需要进一步的临床研究.

关键词:

ангиотензин II 的使用这种高血压,高血压.皮里多克萨尔-5′-酸盐是什么皮鲁瓦米德 ангиотензин II 的使用.血管氨酸阿尔多斯激素系统维生素B6 维生素B6 是一种维生素.

更多相关视频

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Extraction and Purification of Polyphenols from Freeze-dried Berry Powder for the Treatment of Vascular Smooth Muscle Cells In Vitro

Extraction and Purification of Polyphenols from Freeze-dried Berry Powder for the Treatment of Vascular Smooth Muscle Cells In Vitro

Published on: July 5, 2017

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

Antihypertensive Drugs: Vasodilators

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Hypertension IV: Drug Therapy and Lifestyle Modifications

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...

Antihypertensive Drugs: Potassium-Sparing Diuretics

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...